CHINA
China | Data exclusivity comes into effect
Protection of Drug Trial Data on 15 May 2026 with immediate effect, i.e. simultaneously with the Implementing Regulations of the Drug Administration Law (2026 Revisions). The enforcement of...
Protection of Drug Trial Data on 15 May 2026 with immediate effect, i.e. simultaneously with the Implementing Regulations...
Read More
INDONESIA
Indonesia | Patent application procedures updated under Regulation No. 6 of 2026
Indonesia’s Ministry of Law has issued Regulation No. 6 of 2026, introducing updated procedural requirements for patent applications in line with the new Patent Law.   Enacted on 23 February 2026,...
Indonesia’s Ministry of Law has issued Regulation No. 6 of 2026, introducing updated procedural requirements for patent applications in...
Read More
AUSTRALASIA
Extending Protection for Pharmaceuticals | Requirements in Australia, China and Singapore
Our teams across the Asia Pacific explore how pharmaceutical innovators can extend protection for their therapeutic products through patent term extensions (PTEs) and data exclusivity in Australia, China, and Singapore.  A comparison table is provided below which summarises key requirements and timing considerations for...
Our teams across the Asia Pacific explore how pharmaceutical innovators can extend protection for their therapeutic products through patent term extensions (PTEs) and data...
Read More
AUSTRALIA
Australia | Navigating Best Method after NOCO
On 10 April 2026, the Full Federal Court handed down its decision in The NOCO Company v Brown and Watson1. That decision contained significant ramifications for divisional applications in...
On 10 April 2026, the Full Federal Court handed down its decision in The NOCO Company v Brown and...
Read More
AUSTRALIA
IP Australia 2026 Intellectual Property Report
IP Australia has released the fourteenth edition of the 'Australian Intellectual Property Report' (the Report) which presents key movements in IP statistics and explores the links between innovation, collaboration...
IP Australia has released the fourteenth edition of the 'Australian Intellectual Property Report' (the Report) which presents key movements...
Read More
SINGAPORE
IPOS Launches ASPEC+ to streamline patent examination across ASEAN
On 6 April 2026, the Intellectual Property Office of Singapore (IPOS), together with ASEAN partner IP offices, announced the launch of the ASEAN Patent Examination Co-operation Plus (ASPEC+) programme.   For...
On 6 April 2026, the Intellectual Property Office of Singapore (IPOS), together with ASEAN partner IP offices, announced the...
Read More
GREATER CHINA
Double Patenting: A multi-jurisdictional minefield | China, Hong Kong & Southeast Asia
“In China, there is no doctrine preventing an applicant from obtaining multiple patents for obvious variants, patentably indistinct subject matter, or incremental improvements, so long as the claims are...
“In China, there is no doctrine preventing an applicant from obtaining multiple patents for obvious variants, patentably indistinct subject...
Read More
AUSTRALIA
Australia | Lessons from recent interlocutory injunctions in pharmaceutical patent cases
Is it becoming easier to obtain interlocutory injunctions in Australian pharmaceutical patent cases? We provide an overview of recent decisions in Australia’s Federal Court that shine a light on some key lessons for patent owners.  Overview  In...
Is it becoming easier to obtain interlocutory injunctions in Australian pharmaceutical patent cases? We provide an overview of recent decisions in Australia’s Federal Court that...
Read More